[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.172.233.215. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 4, 1968

Evaluation of a New Antibacterial Agent: Cephaloridine (Loridine)

JAMA. 1968;206(6):1289-1290. doi:10.1001/jama.1968.03150060063014
Abstract

Cephaloridine, when administered parenterally, is effective clinically against sensitive strains of gram-positive cocci and certain gram-negative bacilli. At present, it should ordinarily be reserved for use against infections of proved sensitivity in patients who cannot tolerate cephalothin. Cephaloridine has nephrotoxic properties when given in large doses. Other adverse effects that have been reported include changes in hepatic function, hypersensitivity reactions, some instances of cross allergenicity with penicillins, renal tubular necrosis with uremia and death after large doses in some patients with progressive renal disease, and toxic effects on the central nervous system after intrathecal administration.

×